Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
News|Videos|July 18, 2014
Patient Outcomes and PIK3CA Mutations
Author(s)Sara A. Hurvitz, MD
Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, discusses patient outcomes associated with PIK3CA mutations.
Advertisement
Clinical Pearls
Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, discusses patient outcomes associated with PIK3CA mutations.
- A number of studies have analyzed the outcomes of patients with a PIK3CA mutation.
- Preclinical data suggest the PIK3CA mutation may make tumors resistant to trastuzumab.
- Trastuzumab-naïve patients with HER2 amplification and a PIK3CA mutation seem to do better than those who do not. Patients with a PIK3CA mutation who are treated with trastuzumab seem to do worse.
- Patients with a PIK3CA mutation have a lower chance of having a pathologic complete response.
Advertisement
Related to this article
Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.
Mark A. Lewis, MD, explains how oral cabozantinib reduces time toxicity for patients with previously treated, well-differentiated neuroendocrine tumors.
Amr Mohamed, MD, reviews zocilurtatug pelitecan phase 1/2 data in platinum-refractory extrapulmonary neuroendocrine carcinoma.
Halfdan Sorbye, MD, PhD, discusses why accurately distinguishing NET G3 from NEC is critical, as the wrong first-line therapy can shorten survival.
Chrisann Kyi, MD, discusses the 79.3% response rate with sofetabart mipitecan plus bevacizumab in platinum-sensitive ovarian cancer and phase 3 plans.
Hear how a single ctDNA blood draw 3 to 9 weeks into immunotherapy may reveal response earlier than imaging in NSCLC, with Valsamo Anagnostou, MD, PhD.
Lauren Banks, MD, PhD, explains early findings from a pilot study of lifileucel in dedifferentiated liposarcoma and undifferentiated pleomorphic sarcoma, including treatment feasibility, safety, and response durability.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Amivantamab and Hyaluronidase for Recurrent/Metastatic HNSCC
2
Zocilurtatug Pelitecan Shows Activity in epNEC Across DLL3 Expression Levels
3
LITESPARK-011 Raises Questions About RCC Treatment Sequencing
4
Dr Mohamed on Zocilurtatug Pelitecan for Refractory Extrapulmonary NEC
5